Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-4232 is a highly potent, central nervous system (CNS)-penetrant antagonist of the calcitonin gene-related peptide (CGRP) receptor. It was developed as a radiolabeled positron emission tomography (PET) tracer to visualize and quantify CGRP receptor distribution in the brain. The compound was derived from modifications of the CGRP receptor antagonist MK-3207 to enhance CNS penetrance and allow for radiolabeling with carbon-11. [(11)C]MK-4232 has been used in preclinical and clinical imaging studies to map CGRP receptors, which are implicated in migraine pathophysiology. The highest concentrations of binding were observed in the cerebellum and brainstem regions of both rhesus monkeys and humans[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MK-4232.